Company Description
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).
It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial.
The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021.
Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 7, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Michael Cloonan |
Contact Details
Address: 21 Hickory Drive, Suite 500 Waltham, Massachusetts 02451 United States | |
| Phone | 617 819 2020 |
| Website | sionnatx.com |
Stock Details
| Ticker Symbol | SION |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0002036042 |
| ISIN Number | US8294011080 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Cloonan M.B.A. | President, Chief Executive Officer and Director |
| Elena H. Ridloff C.F.A. | Chief Financial Officer and Head of Corporate Development |
| Dr. Charlotte McKee M.D. | Chief Medical Officer |
| Dr. Greg Hurlbut Ph.D. | Co-Founder and Senior Vice President of Discovery Research |
| Dr. Mark Munson Ph.D. | Co-founder and Senior Vice President of Medicinal Chemistry |
| Meghan Bagshaw | Vice President of Programs, Portfolio and Operations |
| Andy Chu | Vice President of Information and Technology |
| Vanya Sagar | Chief People Officer |
| Mara Furlow M.S. | Senior Vice President of Global Regulatory Affairs and Quality |
| Michael Hewitt Ph.D. | Senior Vice President of Chemistry, Manufacturing and Controls |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2025 | 10-K | Annual Report |
| Mar 20, 2025 | 8-K | Current Report |
| Feb 18, 2025 | SCHEDULE 13D | Filing |
| Feb 18, 2025 | SCHEDULE 13D | Filing |
| Feb 18, 2025 | SCHEDULE 13D | Filing |
| Feb 18, 2025 | SCHEDULE 13D | Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |